Belgian biotechnology group Galapagos is testing a new
class of antibiotics that could be used to treat bacterial infections that have
become resistant to other forms of medication.
The group said on Monday that in laboratory tests its
new candidate drug, CAM 1, showed better results than traditional antibiotics
against the bacteria causing MRSA, a life threatening disease sometimes
contracted by hospital patients. Galapagos said it hoped to enter clinical
tests for the drug, which it fully owned, in 2014.
Source: Chicago Tribune
Please share
No comments:
Post a Comment